# Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants

> **NCT02835508** · PHASE1 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-56021927 60 Milligram
- **DRUG:** JNJ-56021927 120 Milligram
- **DRUG:** JNJ-56021927 240 Milligram

## Key facts

- **NCT ID:** NCT02835508
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02835508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02835508, "Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02835508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*